Product Information
BACITRACIN-POLYMYXIN EYE OINT is a generic product labeled by Bausch & Lomb Incorporated, priced at $2.7755 per GM under NDC 24208055555. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jan 26, 1995.
Strength
500; 10000 [USP'U]/g; [USP'U]/g
Manufacturer
Bausch & Lomb IncorporatedNDC
24208055555
Classification
Generic
Dosage Form
OINTMENT
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
BACITRACIN ZINC; POLYMYXIN B SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA064046FDA Approved
1/26/1995
On Market Since
4/25/2008
Pharmacological Classes
Price Statistics
The NADAC for BACITRACIN-POLYMYXIN EYE OINT has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 16.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.7755 per GM |
|---|---|
| All-time high | $3.8331 (Apr 15, 2015) |
| All-time low | $1.7781 (Jul 17, 2024) |
| 52-week high | $3.0278 |
| 52-week low | $2.6947 |
| Median price | $3.0714 |
| Average price | $3.0613 |
| Largest weekly change | +53.8% (Aug 21, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 96% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch & Lomb Incorporated manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Bacitracin Zinc and Polymyxin B Sulfate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Polymyxin-class Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BACITRACIN-POLYMYXIN EYE OINT?
The current National Average Drug Acquisition Cost (NADAC) for BACITRACIN-POLYMYXIN EYE OINT, manufactured by Bausch & Lomb Incorporated, is $2.7755 per GM (NDC 24208055555), effective Sep 30, 2026.
How has the price of BACITRACIN-POLYMYXIN EYE OINT changed over time?
Over the history we have for it, the NADAC for BACITRACIN-POLYMYXIN EYE OINT has declined 16.1%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for BACITRACIN-POLYMYXIN EYE OINT?
Since Nov 28, 2013, the NADAC for BACITRACIN-POLYMYXIN EYE OINT has ranged from a low of $1.7781 (Jul 17, 2024) to a high of $3.8331 (Apr 15, 2015), with a median of $3.0714 per GM.
Are there cheaper alternatives to BACITRACIN-POLYMYXIN EYE OINT?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, HM DOUBLE ANTIBIOTIC OINTMENT, is $0.1066 per GM — about 96% below BACITRACIN-POLYMYXIN EYE OINT.
Who manufactures BACITRACIN-POLYMYXIN EYE OINT?
BACITRACIN-POLYMYXIN EYE OINT (NDC 24208055555) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a generic product.